MAVS and steatosis: First, MASLD characterization and sample size of the cohorts differed: we used 18 samples from people with obesity and MASLD (in fibrosis stage 1 or 2) diagnosed according to Brunt-Kleiner’s criteria37; in contrast, in the previous report, 8 samples with an NAS ≥3 are classified as MASLD, while those with NAS ≤2 without steatosis are classified as non-MASLD,18 and the potential impact of dyslipidemia on MAVS expression was not analyzed.